Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outloo...( Company Expects to Deliver Multiple C...),Health

Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position

CRANBURY, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced positive progress in its three lead clinical programs for lysosomal storage disorders and presented a corporate outlook consisting of multiple clinical milestones and financial guidance for 2009 at the 27th Annual J.P. Morgan Healthcare Conference. The Company also provided an update on its interactions with U.S. and European regulatory agencies that are expected to lead to the commencement of Phase 3 clinical development for Amigal(TM) (migalastat hydrochloride), an oral therapeutic drug candidate for the treatment of Fabry disease. Amicus, along with its partner, Shire Human Genetic Therapies, Inc. (Shire HGT), plans to initiate Phase 3 development of Amigal for the treatment of Fabry disease in the second quarter of 2009. Amicus also reviewed data on the potential for the combination of pharmacological chaperones and enzyme replacement therapy (ERT).

"We continue to make significant advancements in our clinical programs and we expect this to progress through several key milestones which we plan to deliver in 2009. Combined with our financial strength, our partnership with Shire HGT, and the growing breadth of our pharmacological chaperone technology platform, we feel this progress sets the stage for a transformational year for our company," said John F. Crowley, Amicus' President and CEO.

CLINICAL PROGRAM ADVANCEMENTS

Amigal (migalastat hydrochloride) for the treatment of Fabry Disease

Amicus previously announced in August 2008 that it had completed a successful End of Phase 2 meeting with the U.
'/>"/>